The European Medicines Agency (EMA) has issued an opinion on the application for registration of Iloperidone from Vanda Pharmaceuticals. The drug iloperidone is an antipsychotic drug intended for the treatment of schizophrenia and the acute treatment of manic or mixed episodes in bipolar I disorder. The CHMP (Committee for Medicinal Products for Human Use) issued a negative opinion on the granting of marketing authorization registration. Iloperidone works by blocking receptors for dopamine D2 and serotonin 5-HT2 in the brain, which is expected to normalize brain activity. The Committee expressed concern about the breakdown of the drug in the liver in some patients and the concomitant use of other drugs, which may increase the risk of QT prolongation. This document is in "opinion" status.